Phase 3 study results on Deucrictibant for HAE attacks published in The Lancet

Phase 3 study results showing Deucrictibant's rapid and sustained efficacy in treating hereditary angioedema (HAE) attacks were published in The Lancet.

Detected & updated continuously · Source: Nebula